371 related articles for article (PubMed ID: 28143740)
1. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.
Hale M; Mesojednik T; Romano Ibarra GS; Sahni J; Bernard A; Sommer K; Scharenberg AM; Rawlings DJ; Wagner TA
Mol Ther; 2017 Mar; 25(3):570-579. PubMed ID: 28143740
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
3. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
[TBL] [Abstract][Full Text] [Related]
4. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.
Ali A; Kitchen SG; Chen ISY; Ng HL; Zack JA; Yang OO
J Virol; 2016 Aug; 90(15):6999-7006. PubMed ID: 27226366
[TBL] [Abstract][Full Text] [Related]
5. A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.
Sok D; Pauthner M; Briney B; Lee JH; Saye-Francisco KL; Hsueh J; Ramos A; Le KM; Jones M; Jardine JG; Bastidas R; Sarkar A; Liang CH; Shivatare SS; Wu CY; Schief WR; Wong CH; Wilson IA; Ward AB; Zhu J; Poignard P; Burton DR
Immunity; 2016 Jul; 45(1):31-45. PubMed ID: 27438765
[TBL] [Abstract][Full Text] [Related]
6. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
[TBL] [Abstract][Full Text] [Related]
7. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
9. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
Xiang SH; Farzan M; Si Z; Madani N; Wang L; Rosenberg E; Robinson J; Sodroski J
J Virol; 2005 May; 79(10):6068-77. PubMed ID: 15857992
[TBL] [Abstract][Full Text] [Related]
10. Broadly Neutralizing Antibodies for HIV Eradication.
Stephenson KE; Barouch DH
Curr HIV/AIDS Rep; 2016 Feb; 13(1):31-7. PubMed ID: 26841901
[TBL] [Abstract][Full Text] [Related]
11. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.
Anthony-Gonda K; Bardhi A; Ray A; Flerin N; Li M; Chen W; Ochsenbauer C; Kappes JC; Krueger W; Worden A; Schneider D; Zhu Z; Orentas R; Dimitrov DS; Goldstein H; Dropulić B
Sci Transl Med; 2019 Aug; 11(504):. PubMed ID: 31391322
[TBL] [Abstract][Full Text] [Related]
12. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
[TBL] [Abstract][Full Text] [Related]
13. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.
Wu X; Guo J; Niu M; An M; Liu L; Wang H; Jin X; Zhang Q; Lam KS; Wu T; Wang H; Wang Q; Du Y; Li J; Cheng L; Tang HY; Shang H; Zhang L; Zhou P; Chen Z
J Clin Invest; 2018 Jun; 128(6):2239-2251. PubMed ID: 29461979
[TBL] [Abstract][Full Text] [Related]
14. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
15. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
16. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
Brady JM; Baltimore D; Balazs AB
Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
[TBL] [Abstract][Full Text] [Related]
17. Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India.
Makhdoomi MA; Singh D; Nair Pananghat A; Lodha R; Kabra SK; Luthra K
Virology; 2016 Dec; 499():105-113. PubMed ID: 27643887
[TBL] [Abstract][Full Text] [Related]
18. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
19. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120.
Masiero S; Del Vecchio C; Gavioli R; Mattiuzzo G; Cusi MG; Micheli L; Gennari F; Siccardi A; Marasco WA; Palù G; Parolin C
Gene Ther; 2005 Feb; 12(4):299-310. PubMed ID: 15496956
[TBL] [Abstract][Full Text] [Related]
20. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
